Skip to main content
. 2022 May 16;132(10):e145889. doi: 10.1172/JCI145889

Figure 7. Lack of protective effect of kisspeptin agonist on steatosis and NASH progression in hepatic AMPK-knockout mice fed HFD.

Figure 7

C57BL/6J mice fed HFD were injected with either AAV8-U6-M-PRKAA2 shRNA (shAMPK) or AAV8-U6-M-SCRM shRNA (SCRM) prior to kisspeptin agonist (KPA) treatment. (A) Expression of Prkaa2 (encoding AMPKα2) by RT-qPCR. (B) Representative Western blot showing expression of AMPK isoforms. (C) Representative histology of H&E-stained (left) liver sections and Oil Red O–stained (right) liver sections. Quantification of staining is shown. Scale bars: 400 μm. (D) Liver and (E) serum triglycerides (TGs). (F) Serum ALT levels. (G, H, J, and L) Expression of indicated genes by RT-qPCR. (I and M) Representative Western blots showing expression of indicated proteins. (K) Plasma TNF-α levels and (N) ketone levels. Densitometric analyses of blots shown in Supplemental Figure 9; complete unedited blots are shown in Supplemental Figure 10. Data are shown as the mean ± SEM. Student’s unpaired t test; *P < 0.05 versus respective controls.